Karyopharm (KPTI) Officer Executes Broker-Assisted Sale to Cover Taxes

Rhea-AI Filing Summary

Karyopharm Therapeutics (KPTI) Chief Accounting Officer Kristin Abate reported a sale of company common stock on 09/03/2025. The Form 4 shows a broker-assisted sale of 12 shares at $6.78 per share executed under a durable automatic sale instruction plan adopted May 27, 2021, to satisfy withholding tax from vested restricted stock units. After the transaction Abate beneficially owns 9,463 shares directly. The filing is signed by an attorney-in-fact on behalf of Abate on 09/04/2025. The sale is reported as non-discretionary and intended solely for tax withholding.

Positive

• Transaction executed under a pre-established durable sale instruction plan, indicating procedural compliance
• Clear disclosure showing the sale was broker-assisted and non-discretionary to cover tax withholding

Negative

• Insider sale occurred, reducing direct holdings by 12 shares
• Filing reflects a disposition of common stock by a senior officer, which some investors monitor

Insights

Securities/Equity Analyst

TL;DR: Routine, small, tax-withholding sale by an officer under a pre-established plan; not material to investor valuation.

The reported sale is minimal in size—12 shares at $6.78—executed under a durable automatic sale instruction plan to cover withholding tax on vested RSUs. Because the transaction is described as broker-assisted and non-discretionary, it indicates compliance with Rule 10b5-1 practice rather than active trading based on insider information. The remaining direct ownership of 9,463 shares is disclosed, but no additional transactions or derivative positions are reported.

Compliance / Corporate Governance Expert

TL;DR: Proper Form 4 disclosure of a pre-planned tax-withholding sale; shows procedural compliance and timely reporting.

The filing documents that the disposition arose from a sale instruction plan adopted in 2021 and explicitly states the sale was to satisfy tax withholding on RSU vesting. The signature by an attorney-in-fact and the clear explanation meet disclosure requirements. There is no indication of discretionary trading or material change in insider holdings beyond the small reported sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abate Kristin

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S(1)		12	D	$6.78	9,463	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Kristin Abate	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kristin Abate report on Form 4 for KPTI?

The Form 4 reports a broker-assisted sale of 12 shares of Karyopharm Therapeutics common stock at $6.78 per share.

When was the transaction dated and why was it executed?

The transaction date was 09/03/2025, executed pursuant to a durable automatic sale instruction plan to satisfy withholding tax on vested RSUs.

How many KPTI shares does Kristin Abate beneficially own after the sale?

After the reported transaction Abate beneficially owns 9,463 shares directly.

Who signed the Form 4 on behalf of Kristin Abate?

The Form 4 is signed by Nancy Smith as Attorney-in-Fact for Kristin Abate with the signature date 09/04/2025.

Was the sale discretionary or part of a pre-established plan?

The filing states the sale was not a discretionary trade and was effected under a sale instruction plan adopted on May 27, 2021.